Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
|
Thursday, October 22, 2009 |
||
| Session 1 | BONE MARROW FAILURE AND CHILDHOOD MDS - Chair: H. Hasle | |
| 14h00-14h45 | Pathophysiologic links between marrow failure, genomic instability and clonal évolution | N. Young (Bethesda) |
| 14h45-15h30 | Childhood MDS and JMML; biology, diagnosis and treatment | H. Hasle (Aarhus) |
| 15h30-16h00 | Cases and questions to panel | Panel |
| 16h00-16h30 | Coffee break | |
| Session 2 | DIAGNOSTIC WORK-UP OF MDS - Chair: A. Porwit | |
| 16h30-17h00 | Diagnosis and WHO 2008 classification of MDS | A. Porwit (Stockholm) |
| 17h00-17h30 | Cytogenetics and molecular genetics in MDS | B. Schlegelberger (Hannover) |
| 17h30-17h50 | Role of flow cytometry in MDS diagnostics | A.A. van de Loosdrecht (Amsterdam) |
| 17h50-18h10 | The application of array-based technology in MDS diagnostics | A. Pellagatti (Oxford) |
| 18h10-18h30 | New aspects of MDS and “not yet MDS” morphology | B. Bain (London) |
| 18h30-19h00 | Cases and questions to panel | Panel |
| 19h30-20h30 | Posters and welcome reception | |
| 20h30 | Dinner | |
| Friday, October 23, 2009 | ||
| Session 3 | EPIDEMIOLOGY AND CLINICAL EVALUATION OF MDS - Chair: L. Malcovati | |
| 09h00-09h30 | Epidemiology |
D. Bowen (Leeds) |
| 09h30-10h00 | Clinical presentation | M. Jadersten (Stockholm) |
| 10h00-10h30 | Prognosis and risk assessment | L. Malcovati (Pavia) |
| 10h30–11h00 | Cases and questions to panel | A. Porwit (Stockholm) & E. Hellström-Lindberg (Stockholm) |
| 11h00-11h30 | Coffee Break | |
| Session 4 | MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS - Chair: M. Cazzola | |
| 11h30-12h00 | Chronic myelomonocytic leukaemia | D. Bowen (Leeds) |
| 12h00-12h20 | TET2 mutations in MDS and MPNs | M. Fontenay (Paris) |
| 12h20-12h40 | TET2 mutations in MDS and MPNs |
J.H. Janssen (Nijmegen) |
| 12h40-13h00 | Refractory anemia with ringed sideroblasts and excessive thrombocytosis |
M. Cazzola (Pavia) |
| 13h00-14h30 | Lunch discussions at defined tables | |
| Session 5 |
OVERLAPPING SYNDROMES - Chair: D. Bowen |
|
| 14h30-15h00 | MDS with bone marrow fibrosis |
L. Malcovati (Pavia) |
| 15h00-15h30 | Therapy related MDS | P. Fenaux (Paris) |
| 15h30-16h00 | NPM1 – role in AML and MDS | C. Mecucci (Perugia) |
| 16h00-16h30 | Coffee break | |
| Session 6 |
MDS RESEARCH. WHAT HAVE WE LEARNED? - Chair: J. Maciejewski |
|
| 16h30-17h00 | MDS research |
J. Maciejewski (Cleveland) |
| 17h00-17h30 | Epigenetic studies | K. Gronbaeck (Copenhagen) |
| 18h00-18h30 | Animal models – genetically modified mice | R.A. Padua (Paris) |
| 18h30-19h00 | Somatically modified cell and animal models | A. Karsan (Vancouver) |
| 18h30-19h00 | Questions to panel | |
| 20h00-21h00 | Poster presentation | |
| 21h00-22h30 | Dinner | |
| Saturday, October 24, 2009 | ||
| Session 7 | PATHOPHYSIOLOGY - Chair: P. Fenaux | |
| 09h00-09h30 | Apoptosis and erythroid failure in low-risk MDS | E. Hellström-Lindberg (Stockholm) |
| 09h30-10h00 | Molecular biology and genetic pathways in MDS | J. Maciejewski (Cleveland) |
| 10h00-10h30 | Molecular biology and genetic pathways in low-risk MDS | M. Fontenay (Paris) |
| 10h30-11h00 | Clonal evolution and leukaemic transformation |
S. Boehrer (Paris) |
| 11h00-11h30 | Coffee break | |
| Session 8 | BIOLOGY AND TREATMENT OF 5q-SYNDROME - Chair: A. Karsan | |
| 11h30-12h00 | The molecular pathogenesis of MDS with the del (5q) | J. Boultwood (Oxford) |
| 12h00-12h20 | Treatment of 5q-; the pro-lenalidomide view | P. Fenaux (Paris) |
| 12h20-12h40 | Treatment of 5q-; the con-lenalidomide view | M. Jadersten (Stockholm) |
| 12h40-13h00 | Treatment of 5q-; cases and panel discussion | Panel |
| 13h00-14h00 | Lunch discussions at defined tables | |
| Session 9 | SUPPORTIVE CARE IN MDS - Chair: M. Cazzola | |
| 14h00-14h30 | Transfusion therapy in MDS | L. Malcovati (Pavia) |
| 14h30-15h00 | Iron metabolism and transfusion iron overload | M. Cazzola (Pavia) |
| 15h00-15h20 | Treatment of transfusion iron overload in MDS; the pro-chelation view | C. Rose (Lille) |
| 15h20-15h40 | Treatment of transfusion iron overload in MDS; the con-chelation view | D. Bowen (Leeds) |
| 15h40-16h00 | Management and treatment of thrombocytopenia | G. Garcia-Manero (Houston) |
| 16h00-16h30 | Coffee Break | |
| Session 10 | CURATIVE TREATMENT - Chair: T. De Witte | |
| 16h30-17h00 | Ablative SCT ± preceding chemotherapy | T. De Witte (Nijmegen) |
| 17h00-17h30 | Non myelomablative stem cell transplantation | N. Kroeger (Hamburg) |
| 17h30-18h00 | Treatment of paediatric MDS | C. Niemeyer (Freiburg) |
| 18h00-18h30 | Cases and questions to panel | Panel |
| 20h30 | Conference Dinner and Jazz Music | |
|
Sunday, October 25, 2009 |
||
| Session 11 | TREATMENT OF LOW-RISK MDS - Chair: E. Hellstrom-Lindberg | |
| 08h30-09h00 | Growth factor treatment of low-risk MDS | E. Hellström-Lindberg (Stockholm) |
| 09h00-09h20 | Immunosupression in low-risk MDS | N. Young (Bethesda) |
| 09h20-09h40 | Low-risk MDS: ongoing trials at clinicaltrials.gov | M. Cazzola (Pavia) |
| 09h40-10h30 | Leukaemia Net Guidelines and cases low-risk MDS | Panel |
| 10h00-10h30 | Coffee break | |
| Session 12 | NON-CURATIVE TREATMENT OF HIGH-RISK MDS - Chair: G. Garcia-Manero | |
| 10h30-10h50 | Induction chemotherapy and low-dose chemotherapy | M. Lübbert (Freiburg) |
| 10h50-11h20 | Azacytidine in MDS | P. Fenaux (Paris) |
| 11h20-11h40 | Decitabine in MDS | M. Lübbert (Freiburg) |
| 11h40-12h10 | High-risk MDS: HIDACi and ongoing trials at clinicaltrials.gov | G. Garcia-Manero (Houston) |
| 12h10-13h00 | Leukaemia Net Guidelines and cases high-risk MDS | Panel |
| 13h00 | Adjourn | Chairs |
